PEO1 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
TO14 Cell Line
Invented by Simon Langdon from The University of Edinburgh
Invented at Cancer Research UK Edinburgh Centre
- Datasheet
- References (6)
- Inventor Info
Info
| Catalogue Number | 151680 |
| Host | Human |
| Tissue | Ovary |
| Disease Keywords | Adenocarcinoma |
| Relevance | The TO14 cell line is one of nine from the PE ovarian adenocarcinoma panel (derived from 4 patients at varying stages of ovarian cancer, isolated from various malignant sites, and at various treatment stages) which provides a model system for research into the mechanism of oestrogen action on ovarian adenocarcinoma tumour cells, and for the study of efficacy and toxicity of oestrogen protagonists. TO14 is an adherent cell line derived from a metastasis to the omentum obtained at hysterectomy from a patient with a well differentiated serous adenocarcinoma. TO14 exhibits poor growth in semi-solid medium (agar). TO14 is from the same patient as PEO23 cell line. This is a oestrogen receptor negative cell line. Cell line morphology: epithelial; stellate in shape and producing hemicystic colonies which grow upwards from the substrate and detach as spheres. |
| Research Area | Cancer, Drug Discovery & Development |
| Growth/Phenotype Keywords | Adherent |
| Recommended Growing Conditions | RPMI 1640 + 2mM Glutamine + 2mM Sodium Pyruvate + 10% Foetal Bovine Serum (FBS). |
| Cellosaurus ID | CVCL_2734 |
PEO4 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
PEO6 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
PEO16 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
PEO23 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
PEA1 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
PEA2 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
PEO14 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
PEO1-CDDP Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
Antigen/Gene or Protein Targets: Human ovarian cancer; oestrogen receptor, drug resistance, cisplatin resistance
0
reviews
2
references
1
supplier
References: 6 entries
Langdon et al. 1990. Br J Cancer. 62(2):213-6. PMID: 2386737.
Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines.
Europe PMC ID: 2386737
Langdon et al. 1988. Cancer Res. 48(21):6161-5. PMID: 3167862.
Langdon et al. 1988. Cancer Res. 48(21):6166-72. PMID: 3167863.
Effect of sodium butyrate and other differentiation inducers on poorly differentiated human ovarian adenocarcinoma cell lines.
Europe PMC ID: 3167862
Characterization and properties of nine human ovarian adenocarcinoma cell lines.
Europe PMC ID: 3167863
Add a reference
References: 6 entries
Langdon et al. 1990. Br J Cancer. 62(2):213-6. PMID: 2386737.
Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines.
Langdon et al. 1988. Cancer Res. 48(21):6161-5. PMID: 3167862.
Langdon et al. 1988. Cancer Res. 48(21):6166-72. PMID: 3167863.
Effect of sodium butyrate and other differentiation inducers on poorly differentiated human ovarian adenocarcinoma cell lines.
Characterization and properties of nine human ovarian adenocarcinoma cell lines.
Add a reference
